• Explore /
  • Poster
  • / MK-5684 (ODM-208), a CYP11A1 inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) with and without AR-LBD mutations: CYPIDES phase 2 results.

MK-5684 (ODM-208), a CYP11A1 inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) with and without AR-LBD mutations: CYPIDES phase 2 results.

Abstract Poster

Authors

Karim Fizazi

Karim Fizazi

Gustave Roussy, University of Paris-Saclay, Villejuif, France

Karim Fizazi , Guilhem Roubaud , Alice Bernard-Tessier , Gwenaelle Gravis , Aude Flechon , Raffaele Ratta , Philippe Barthelemy , Robert J. Jones , Omi Parikh , Arif Hussain , Hans van der Voet , Natalie Cook , Niamh Peters , Minna Tanner , Robert Hugh Jones , Chris Garratt , Pasi Pohjanjousi , Tarja Ikonen , Christian Heinrich Poehlein , Emmanuel S. Antonarakis

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03436485

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr 159)

DOI

10.1200/JCO.2024.42.4_suppl.159

Abstract #

159

Poster Bd #

G9

Abstract Disclosures

Similar Posters

First Author: Karim Fizazi

First Author: Alice Bernard-Tessier

First Author: Daniel P. Petrylak

First Author: Michael J. Morris